- Straits Times Index3,277.91-0.01%
- Nikkei21,464.23+0.15%
- Hang Seng28,629.920+0.41%
- FTSE 1007,167.39-0.85%
- BTC-USD3,928.91-1.14%
- S&P 5002,780.64-0.15%
- Dow25,903.42-0.20%
- Nasdaq7,482.96-0.08%
- Gold1,330.10-1.32%
- Crude Oil56.84-0.56%
- 10-Yr Bond2.6930+1.47%
- FTSE Bursa Malaysia1,730.68+0.26%
- Jakarta Composite Index6,537.77+0.38%
- PSE Index7,931.30-0.10%
Cannabis Stocks
58.46k followers • 25 symbols Watchlist by Yahoo Finance
Follow this list to discover and track the stock of publicly traded companies with exposure to cannabis
25 symbols
Get the Yahoo Finance app
- Free real-time data
- News and price alerts
- Add and edit holdings
- Track performance
- Create multiple watchlists
- Market Realist•12 minutes ago
Today’s Gains and Losses in the Cannabis Sector: Mid-Day Update
Today's Gains and Losses in the Cannabis Sector: Mid-Day UpdateCannabis stock lossesToday remained mixed for the cannabis sector with some major stocks continuing to decline at around 11:55 AM ET. Canopy Growth (WEED)(CGC) continued to trend lower
Market Realist•14 minutes agoGILD or ABBV: Which Is Expected to Report Faster Revenue Growth?
GILD or ABBV: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Revenue projections for 2019In its fourth-quarter earnings presentation, Gilead Sciences (GILD) guided for product sales in the range of $21.3 billion–$21.8 billion
- Market Realist•19 minutes ago
Does CannTrust Look Cheap?
Why CannTrust Is Trending Higher in February(Continued from Prior Part)CannTrust’s valuationsCannabis stocks (HMMJ) experienced a steep sell-off in December along with the broader markets. This sell-off led to the companies in the cannabis sector
- Market Realist•2 hours ago
What Analysts Are Recommending for GILD and ABBV in February
GILD or ABBV: Which Is a Better Biotech Pick This Month?Share price movements On February 15, Gilead Sciences (GILD) closed at $67.59, 1.84% higher than its previous closing price, 12.05% higher than its 52-week low of $60.32, and 18.29% lower than
- Market Realist•2 hours ago
What Analysts Recommend for CannTrust in February
Why CannTrust Is Trending Higher in February(Continued from Prior Part)Analyst ratingsEarlier in this series, we discussed how CannTrust (CNTTF) has performed so far this year in 2019. The stock is all set to up-list on the New York Stock Exchange
- Zacks•3 hours ago
Tilray's Deal to Buy Hemp Food Maker Bolsters Marijuana ETF
Tilray's deal to acquire the hemp food maker Manitoba Harvest has bolstered the outlook of the already high-flying marijuana ETF.
- Market Realist•3 hours ago
Canopy Growth Restates Earnings Figure, Stock Sinks
Canopy Growth Restates Earnings Figure, Stock SinksCanopy Growth On February 20, Canopy Growth (WEED) (CGC) issued a press release saying that it had reported an incorrect number for adjusted EBITDA for the nine months that ended on December 31,
- Market Realist•3 hours ago
Why CannTrust Is Trending Higher in February
Why CannTrust Is Trending Higher in FebruaryCannTrust’s gains CannTrust (CNTTF) has been trending higher ever since the beginning of this year. The stock has returned nearly 75% YTD as of February 20. In February alone, the company returned about
- Motley Fool•4 hours ago
5 Reasons to Buy Small-Cap Pot Stocks Instead of Large-Cap Marijuana Stocks
Bigger isn't necessarily better when it comes to investing in the cannabis industry.
- Zacks•4 hours ago
Another Round of Slight Gains Amid Choppy Session
Another Round of Slight Gains Amid Choppy Session
- Motley Fool•4 hours ago
What This Beer Giant Just Said About Marijuana Stocks
Constellation Brands offered a look into marijuana's future at a key industry conference this week.
- Motley Fool•5 hours ago
3 Arguments For and Against Buying Aurora Cannabis
Strong cases can be made for owning or avoiding the most polarizing pot stock in the world.
- Motley Fool•5 hours ago
3 Key Things From Canopy Growth's Earnings Call That Investors Should Know
Canopy Growth's CEO and CFO talk cannabis-infused beverages, when the company's hemp-derived CBD products could be available in the U.S., and more.
- Market Realist•5 hours ago
How Charlotte’s Web Holdings’ Upside Potential Compares to Peers
How Charlotte’s Web Holdings’ Upside Potential Compares to PeersAnalystsCharlotte’s Web Holdings (CWBHF) has received a “strong buy” rating from one analyst, while three analysts polled by Thomson Reuters on February 20 have rated it as a
- Market Realist•6 hours ago
How Analysts View Aphria in February
Analysts' Ratings for ACB, CRON, and APHA in February(Continued from Prior Part)Aphria Last week, Aphria’s (APHA) board provided some relief to investors with its findings on the LATAM asset acquisitions. While the board did find conflicts in the
- Motley Fool•20 hours ago
Stock Market Today: CVS Battles Headwinds and Tilray Enters the US Hemp Market
Stocks climbed on optimism about interest rates.
- Motley Fool•20 hours ago
This Tiny Cannabis Company Hits a Tilray Payday
Top marijuana stock Tilray is acquiring a little-known pot stock that catapults it into hemp edibles.
- Zacks•23 hours ago
Forget Mixed Pot Earnings; Bet on ETF on Growth Prospects
Key marijuana companies came up with mixed earnings, but that should not hurt the pot ETF.
- Market Realist•23 hours ago
Aurora Cannabis: Analysts’ Consensus Target Price in February
Analysts' Ratings for ACB, CRON, and APHA in February(Continued from Prior Part)Aurora CannabisAurora Cannabis (ACB) has been almost flat since it reported its earnings on February 11. To learn more about the company’s earnings, read Aurora
- Motley Fool•yesterday
Tilray Leapfrogs Aurora Cannabis and Canopy Growth in the U.S. Hemp Market
Tilray's acquisition of the world's largest hemp food company could give the Canadian marijuana producer an edge over its top rivals.
- Market Realist•yesterday
Tilray to Acquire Manitoba Harvest
Tilray to Acquire Manitoba HarvestTLRY moves higherEarly on February 20, Tilray (TLRY) was moving higher after it announced the acquisition of Manitoba Harvest. The purchase price for Manitoba Harvest was 419 million Canadian dollars, and the
- Market Realist•yesterday
Cronos Group: Analysts’ Recommendations in February
Analysts' Ratings for ACB, CRON, and APHA in February(Continued from Prior Part)Cronos Group Cronos Group (CRON) hasn’t reported its earnings yet. Cronos Group has been one of the top choices for investors (HMMJ) along with Canopy Growth (WEED),
- Zacks•yesterday
AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review
AbbVie's (ABBV) new drug application for its late-stage candidate, upadacitinib, gets a priority review status from the FDA for treating rheumatoid arthritis in adult patients.
- Motley Fool•yesterday
Stock Market News: Pot Stocks Perk Up While Tesla Loses Its Top Lawyer
Quiet activity Wednesday morning belied nervousness about the Fed's latest minutes.
- Market Realist•yesterday
Analysts’ Ratings for ACB, CRON, and APHA in February
Analysts' Ratings for ACB, CRON, and APHA in FebruaryRatings for cannabis stocks On February 19, several investment firms upgraded their target prices for Canopy Growth (WEED) (CGC). However, GMP Securities took a cautionary stance by downgrading
